88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 389
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Brian M. Goff M.B.A. | CEO & Director | 1.23M | N/A | 1969 |
Ms. Cecilia Jones | Chief Financial Officer | 403.36k | N/A | 1975 |
Mr. James William Burns | Corp. Sec. & Chief Legal Officer | 660.33k | N/A | 1978 |
Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of R&D | 769.2k | N/A | 1980 |
Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1949 |
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1946 |
Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | N/A | N/A | 1953 |
Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1956 |
Mr. T. J. Washburn Jr. | Principal Accounting Officer | N/A | N/A | 1981 |
Dr. Clive Patience Ph.D. | Chief Technical Operations Officer | N/A | N/A | 1964 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 7; Compensation: 6.